The purpose of the study is to see how well Concizumab works in preventing bleeding episodes compared to the previous treatment the children were receiving. The study will involve children who have not used Concizumab before. Participants will receive regular injections of Concizumab over a period of time, and the number of bleeding episodes they experience will be monitored and compared to their previous treatment.

Throughout the study, researchers will also keep track of any side effects or reactions to the medication, such as injection site reactions or the development of antibodies against Concizumab. The study aims to provide valuable information on the safety and effectiveness of Concizumab in managing bleeding episodes in young children with hemophilia.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

During the initial part of the study, participants will receive either the medication or the placebo for a period of 24 weeks. The study will monitor how the treatment affects lung function, specifically looking at the forced vital capacity, which is the total amount of air a person can exhale after taking a deep breath. Following this period, there is an option to continue in an extended phase of the study for an additional 24 weeks.

During the study, participants will receive either Eloralintide or a placebo through subcutaneous use, which means the medication is injected into the fatty tissue just under the skin. The medication is provided in a pre-filled syringe for once-weekly administration. This is a randomized and double-blind study, meaning that neither the participants nor the researchers know beforehand which treatment is being administered. This method is used to ensure the results are as objective as possible.

Participants in this study will be assigned to receive either MET097 or a placebo. The study is designed to compare how much body weight changes over a specific period of time. During the course of the trial, individuals will receive their assigned treatment once every week. The process involves monitoring weight changes and other health factors over a long period, extending up to 84 weeks, to observe the impact of the medication on overall health.

Participants will be compared against two other options. One option is Trimbow, which contains the same three active ingredients. The other comparison involves using beclometasone dipropionate alone. Some individuals may also receive a placebo. The study uses a cross-over design, meaning that participants will receive different treatments at different times during the course of the study to see how each one affects their breathing.

One of the main ways the study looks at how well the medicine works is by measuring the forced expiratory volume in 1 second, which is a test that calculates how much air a person can exhale quickly to check lung function. The study tracks these changes over a period of time to see how the different inhaled medications affect breathing capacity and overall control of the condition.

During the study, some participants will receive the active medicine, while others will receive a placebo. The research involves monitoring how the medicine affects the body over a period of time to see if it can change the way the disease progresses. The course of the study includes regular check-ups to observe any changes in health or how the lungs are functioning.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

The purpose of the study is to find out if cagrilintide semaglutide is at least as good as tirzepatide at lowering blood sugar levels, and whether it might be better at helping people lose weight. The study will also look at other health measures such as blood pressure, waist size, cholesterol levels, and overall quality of life. Additionally, the study will check how safe these medications are and what side effects people may experience while taking them.

People taking part in this study will receive either cagrilintide semaglutide or tirzepatide for 60 weeks. During this time, they will continue taking their current diabetes medications. Throughout the study, participants will have regular visits where their blood sugar levels, body weight, blood pressure, and other health measurements will be checked. Blood tests will be done to measure a substance called HbA1c, which shows average blood sugar levels over the past few months, as well as cholesterol and other blood fats. Participants will also be asked to complete questionnaires about their physical health and quality of life. The study team will monitor for any side effects, including episodes of low blood sugar, which can happen when blood sugar drops too much.

The purpose of the study is to evaluate how well these new combinations of immune system treatments work compared to dostarlimab alone in people with this type of cancer that shows the PD-L1 marker. The main measure of success will be looking at how many people experience either complete disappearance of their tumors or significant shrinking of their tumors during treatment. Participants will be assigned randomly to receive one of the treatment combinations, and the study will follow them for up to 24 months to track how their cancer responds.

During the study, participants will receive their assigned treatment through infusions into a vein, and doctors will regularly check how the tumors are responding using imaging scans and physical examinations. Tissue samples from the tumor will be needed to confirm that the cancer meets the study requirements and to check for the PD-L1 marker. The study is designed as an open-label trial, which means both the participants and their doctors will know which treatment is being given. This is a platform study using a master protocol, which means it is set up in a way that allows testing of multiple treatment combinations at the same time.

People taking part in this study will have schizophrenia with symptoms that have gotten worse and will either be in the hospital or need to be in the hospital because of their condition. Their symptoms must have started getting worse within the past two months. Before joining the study, they must have been treated with other antipsychotic medications that worked for them in the past year. During the study, participants will be randomly assigned to receive either the brexpiprazole medication or placebo, and neither they nor their doctors will know which one they are getting. The treatment will be given by mouth as tablets.

The study will measure how much the symptoms change from the beginning of the study to week six. Doctors will use a standard rating scale to measure the symptoms of schizophrenia throughout the study period. The medication will be given once a week, and the study will track how well it works and whether it is safe for people with acute schizophrenia.

During the study, participants will receive treatment for up to 12 months. The researchers will measure several things to see if the treatment is helping, including changes in body weight and appetite over a 12-week period. Body weight will be tracked from the beginning of the study, and appetite will be measured using a questionnaire that asks specific questions about eating and food-related concerns. The study will also look at muscle mass using imaging scans such as CT or MRI, which are types of medical imaging that create detailed pictures of the inside of the body. Physical function will be tested through simple exercises like a chair stand test, and daily physical activity levels will be monitored.

Throughout the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. Participants will also complete questionnaires about their quality of life, how severe their symptoms are, and whether they notice any changes in their condition. Blood samples will be taken to measure the levels of the medication in the body. The study will track overall health outcomes and how the cancer responds to ongoing treatment during this time.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

The trial investigates whether a medication called Orforglipron, taken as a tablet once daily by mouth, can help reduce the number of incontinence episodes experienced each week. Orforglipron belongs to a class of medications known as GLP-1 receptor agonists, which work by mimicking a natural hormone in the body that helps regulate appetite and body weight. By potentially helping participants lose weight, this medication may also reduce pressure on the bladder and improve incontinence symptoms. Some participants will receive placebo instead of the active medication.

The study aims to determine if Orforglipron is more effective than placebo in decreasing the frequency of urinary leakage episodes. Participants will take one tablet daily throughout the treatment period, and their incontinence episodes will be monitored and recorded. This is a Phase 3 trial sponsored by Eli Lilly, designed to evaluate both the effectiveness and safety of the medication in this specific patient population.

The purpose of the study is to find out what dose of GSK4524101 can be given safely, either alone or together with niraparib, and to see if the combination of these two drugs can help slow down or stop the growth of cancer. The study is divided into two parts. In the first part, small groups of people will receive increasing doses of GSK4524101 alone or combined with niraparib to find the highest dose that can be given without causing serious side effects. This part will also include a group to test whether taking GSK4524101 with food affects how the body processes the medication. In the second part, a larger group of people with the specific type of breast cancer described above will receive the combination of GSK4524101 and niraparib at a dose determined to be safe from the first part, to learn more about whether this combination can help shrink tumors.

Throughout the study, participants will have regular check-ups where doctors will monitor for any side effects and take blood samples to measure the amount of medication in the body. The study will also assess how well the treatment works by looking at whether tumors shrink or stop growing, and how long any positive effects last. Participants in the first part will help determine the safest dose to use, while those in the second part will help show whether the combination treatment can provide benefit for people with this specific type of breast cancer who have not previously received a PARP inhibitor.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

During the study, participants will receive either NNC0487-0111, placebo, or standard diabetes medications including metformin and a type of medication called SGLT2 inhibitor (dapagliflozin). The treatment period will last for 36 months, during which participants will need to wear a special device that continuously monitors their blood sugar levels.

The study will measure several health indicators, including changes in blood sugar control (HbA1c), body weight, blood pressure, and various blood tests. Researchers will also monitor kidney function and check for any side effects of the treatment. This research will help determine the most effective and safe dose of the new medication for future use in treating diabetes.

The study aims to understand the long-term safety and effectiveness of efavaleukin alfa in treating people who have moderate to severe Ulcerative Colitis. This research is a continuation of a previous study, allowing researchers to gather information about how well the medication works and how safe it is when used for an extended period.

During this long-term extension study, participants will continue receiving efavaleukin alfa treatment for up to two years. Throughout this time, doctors will monitor various aspects of the participants’ health, including how well their digestive system is healing and whether their symptoms are improving. They will also keep track of any side effects that may occur during the treatment period.

The study involves patients taking either efavaleukin alfa or placebo while continuing their current medications such as 5-aminosalicylates, corticosteroids, budesonide, beclomethasone dipropionate, or other immune system medications like azathioprine, 6-mercaptopurine, or methotrexate. The main purpose is to evaluate if efavaleukin alfa can help patients achieve clinical remission after 12 weeks of treatment.

During the study, doctors will monitor how well the treatment works by examining the digestive tract and checking for improvements in symptoms. They will also keep track of any side effects that may occur. The study is designed as a double-blind study, which means neither the patients nor the doctors know who is receiving the actual medication or the placebo during the treatment period.

The purpose of this research is to assess how safe and well-tolerated NBI-1065845 is when taken as an additional treatment alongside regular antidepressant medication. The study medication comes in the form of oral tablets that participants take along with their current antidepressant treatment.

This is a long-term study that lasts for approximately 52 weeks (one year). During this time, all participants receive the study medication NBI-1065845 while continuing their current antidepressant treatment at the same dose they were taking before joining the study. The study team monitors participants’ health and any side effects that may occur throughout the treatment period.

The purpose of this research is to evaluate how effective UGN-104 is at removing tumors in patients with this type of cancer. The medication will be given directly into the upper urinary tract through a procedure called intravesical administration. Each patient will receive six treatments of the medicine over a treatment period that can last up to 12 months.

After completing the treatment, patients will have a check-up approximately 5 weeks after their final dose to determine if the treatment was successful in eliminating the cancer. The study will continue to monitor patients to see how long the treatment effects last and to check for any side effects. Throughout the study, doctors will perform various tests to ensure patient safety, including blood tests and imaging of the urinary tract.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The purpose of this research is to determine if AZD0780 can reduce the risk of serious cardiovascular events such as heart attacks, strokes, and problems with blood flow to the legs in people with cardiovascular disease. The medication will be tested in addition to patients’ regular cholesterol-lowering treatments.

During the study, participants will receive either AZD0780 or a placebo for up to 54 months. The study team will monitor participants for any cardiovascular events, including heart-related death, heart attacks, strokes, severe leg circulation problems, and emergency procedures to restore blood flow. Throughout the study, participants will continue their usual heart medications, including their regular cholesterol-lowering treatments.

The purpose of this research is to determine if using these two medications together is more effective than using bevacizumab by itself in treating ovarian cancer. The study specifically looks at patients who have recently been diagnosed with advanced stages of the disease. Both medications are types of targeted therapy – bevacizumab works by affecting blood vessel growth in tumors, while trastuzumab deruxtecan is an antibody-drug conjugate that specifically targets cancer cells expressing the HER2 protein.

During the study, patients will receive treatment for up to 24 months. The medications will be given through regular infusions at specified intervals. Throughout the treatment period, doctors will monitor patients’ responses to the therapy and track any changes in their condition. This research is particularly focused on patients whose cancer shows specific levels of a protein called HER2 on their tumor cells.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The purpose of this study is to determine if NBI-1065845 is effective and safe compared to placebo when used as an additional treatment for people with moderate to severe depression. Participants in this study will continue taking their regular antidepressant medication while also receiving either the study drug or placebo.

The study will monitor changes in depression symptoms over an 8-week period. Participants will need to attend regular appointments for evaluations of their depression symptoms using standardized rating scales that measure the severity of depression and how it affects daily functioning.

The purpose of the study is to evaluate how well the combination treatment works in improving lung function and controlling asthma symptoms in participants aged 12 years and older. Participants will be randomly assigned to receive either the combination treatment, one of the individual medications, or a placebo. The study will last for four weeks, during which participants will use the inhaler as directed and attend regular check-ups to monitor their progress. The study aims to see if the combination treatment can provide better control of asthma symptoms compared to the individual medications or placebo.

Throughout the study, participants will be monitored for any changes in their asthma symptoms and overall health. The study will also track any side effects that may occur. By the end of the study, researchers hope to gather valuable information on the effectiveness and safety of the combination treatment for managing asthma. This information could help improve treatment options for people living with asthma in the future.

The main purpose of this study is to determine if tezepelumab can reduce the number of COPD flare-ups (also called exacerbations) in patients. During the study, participants will receive either tezepelumab or placebo through subcutaneous injection using a pre-filled syringe. The treatment period will last for approximately 76 weeks.

The medication being tested, tezepelumab (also known as MEDI9929), is already approved for other uses and is being studied to understand if it can help people with COPD. Throughout the study, doctors will monitor how well the treatment works and check for any side effects. Participants will need to continue using their regular COPD medications during the study period.

The purpose of the study is to evaluate how well the new combination works as a first-line treatment for patients with this type of cancer. Participants in the study will be randomly assigned to receive either the new combination or the standard treatment. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure the results are unbiased. The study will take place over a period of time, with regular assessments to monitor the progress and health of the participants.

Throughout the study, researchers will focus on key outcomes such as progression-free survival, which measures how long patients live without the cancer getting worse, and overall survival, which measures how long patients live overall. The study will also look at the safety of the treatments and any side effects that may occur. By the end of the study, the goal is to determine if the new treatment combination offers a better option for patients with this type of cancer.

Participants in the study will be randomly assigned to receive either the combination of Baxdrostat and Dapagliflozin or Dapagliflozin with a placebo. A placebo is a substance with no active medication. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, ensuring unbiased results. The treatment period will last up to 60 days, and participants will take the medication in the form of tablets.

The study aims to monitor the health of the participants over time, focusing on changes in kidney function and heart health. The researchers will look for any significant decline in kidney function, the need for dialysis or kidney transplant, and any heart-related deaths. The study will also track changes in blood pressure and other health markers. This research hopes to provide valuable insights into better treatment options for people with CKD and high blood pressure.

The purpose of the study is to compare how well these treatment combinations work in controlling the cancer. Participants will receive one of the treatment combinations and will be monitored over time to see how their cancer responds. The study will involve regular visits to the clinic for treatment and assessments, which will include various tests to check the progress of the cancer and the overall health of the participants.

Throughout the study, participants will receive their treatments through an infusion, which means the medication will be given directly into a vein. The study aims to provide valuable information on which treatment combination might be more effective for patients with this specific type of colorectal cancer. The trial will continue until enough information is gathered to make a clear comparison between the two treatment options.

The purpose of the study is to evaluate how well seltorexant works when used alongside other antidepressants, specifically those known as SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors). The study will compare the effects of taking seltorexant with a placebo, which looks like the medication but does not contain the active ingredient. The study aims to see if seltorexant can improve depressive symptoms and help maintain these improvements over time.

Participants in the study will take part in two main parts. In the first part, the effectiveness of seltorexant in improving symptoms of depression will be assessed. In the second part, the focus will be on whether seltorexant can help prevent the return of depressive symptoms after initial improvement. The study will involve taking the medication in the form of a film-coated tablet by mouth. The trial is designed to ensure the safety and effectiveness of seltorexant as an additional treatment for those who have not fully responded to their current antidepressant therapy.

The purpose of the study is to compare the effects of obefazimod with a placebo in managing Crohn’s disease symptoms. Participants will take the medication in the form of a hard capsule, which is taken orally. The study will be conducted in phases, including an induction phase to start the treatment, a maintenance phase to continue the treatment, and an extension phase to further evaluate safety and tolerability. The study will last for a period of up to 100 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, researchers will assess various aspects of the treatment, such as its ability to reduce disease activity and improve symptoms. They will also monitor for any side effects or adverse events to ensure the safety of the participants. The ultimate goal is to determine if obefazimod can be a beneficial treatment option for those living with Crohn’s disease.

The purpose of the study is to see if Levetiracetam XR can reduce the frequency of seizures in patients with drug-resistant focal onset seizures. Participants in the study will receive either the extended-release levetiracetam, the immediate-release levetiracetam, or a placebo. The study will last for a total of 12 weeks, during which the participants will take the medication once daily. Throughout the study, the frequency of seizures will be monitored to assess any changes or improvements.

Participants will be asked to keep a diary of their seizures and any side effects they experience. The study will also look at how the treatment affects the participants’ quality of life and their satisfaction with the medication. The goal is to find out if Levetiracetam XR can offer a better treatment option for those with difficult-to-treat epilepsy, potentially leading to fewer seizures and an improved quality of life.